Antimicrobial treatment of nosocomial meticillin-resistant Staphylococcus aureus (MRSA) pneumonia: current and future options.
about
Targeting RNA polymerase primary σ70 as a therapeutic strategy against methicillin-resistant Staphylococcus aureus by antisense peptide nucleic acidNosocomial methicillin resistant Staphylococcus aureus pneumonia - epidemiology and trends based on data of a network of 586 German ICUs (2005-2009)No Outbreak of Vancomycin and Linezolid Resistance in Staphylococcal Pneumonia over a 10-Year Period.The licorice pentacyclic triterpenoid component 18β-glycyrrhetinic acid enhances the activity of antibiotics against strains of methicillin-resistant Staphylococcus aureus.Phage ΦPan70, a Putative Temperate Phage, Controls Pseudomonas aeruginosa in Planktonic, Biofilm and Burn Mouse Model AssaysClonal distribution and possible microevolution of methicillin-resistant Staphylococcus aureus strains in a teaching hospital in Malaysia.Comparison of Linezolid and Vancomycin for Methicillin-Resistant Staphylococcus aureus Pneumonia: Institutional Implications.Targeted therapy against multi-resistant bacteria in leukemic and hematopoietic stem cell transplant recipients: guidelines of the 4th European Conference on Infections in Leukemia (ECIL-4, 2011).Nosocomial methicillin-resistant Staphylococcus aureus (MRSA) pneumonia: linezolid or vancomycin? - Comparison of pharmacology and clinical efficacy.Surveillance and management of multidrug-resistant microorganisms.Safety evaluation of cephalosporins based on utilization and adverse drug events: analysis of two databases in China.Current use of daptomycin in cardiac surgery and postoperative intensive care.Emerging drugs on methicillin-resistant Staphylococcus aureus.Treating paediatric community-acquired pneumonia in the era of antimicrobial resistance.Antibiotic prophylaxis in craniotomy: a review.Bacterial Adaptation during Chronic Respiratory Infections.Ceftaroline fosamil as first-line versus second-line treatment for acute bacterial skin and skin structure infections (ABSSSI) or community-acquired bacterial pneumonia (CABP).Pharmacodynamics, pharmacokinetics and clinical efficacy of telavancin in the treatment of pneumonia.Trimethoprim/sulfamethoxazole versus vancomycin in the treatment of healthcare/ventilator-associated MRSA pneumonia: a case-control study.Routine use of Staphylococcus aureus rapid diagnostic test in patients with suspected ventilator-associated pneumonia.Rapid determination of methicillin resistance among Staphylococcus aureus clinical isolates by colorimetric methods.Managing Severe Community-Acquired Pneumonia Due to Community Methicillin-Resistant Staphylococcus aureus (MRSA).Emergence of spontaneous bacterial peritonitis due to enterococci - risk factors and outcome in a 12-year retrospective study.Relationship between antibiotic consumption, oropharyngeal colonization, and ventilator-associated pneumonia by Staphylococcus aureus in an intensive care unit of a Brazilian teaching hospital.Retrospective analysis of relationships among the dose regimen, trough concentration, efficacy, and safety of teicoplanin in Chinese patients with moderate-severe Gram-positive infections.[Criteria for treating MRSA in sputum].A New Synthetic Peptide with In vitro Antibacterial Potential Against Escherichia coli O157:H7 and Methicillin-Resistant Staphylococcus aureus (MRSA).Subinhibitory concentrations of pinocembrin exert anti-Staphylococcus aureus activity by reducing α-toxin expression.Membrane-damaging potential of natural L-(-)-usnic acid in Staphylococcus aureus.
P2860
Q28478754-EC2D610C-2F9C-4FD5-8134-EC6703A37C31Q33773159-747046FD-490F-40AD-9D22-65EBE7408FC4Q35785093-14BAB7D6-8663-4079-A283-03DFB16717F9Q35896916-9694AE63-704E-4490-9DF5-D6D3884C387BQ36076253-FAD3B2D0-C956-4527-9840-37CAB14F7D4CQ36782390-8CDF2E8C-E6E3-466A-8149-781E52C684DDQ37120918-EFE0CC07-6EE7-4355-A008-E4CF72EAB817Q37377897-B620FE86-FD97-4809-8AC4-A3407BFE6644Q37821604-165E7D9E-21E1-47FA-AE08-FA10C4A0AE45Q37912231-12E367E0-5084-443B-879A-3EFEB94E5094Q38019585-D2CDA409-19C1-4BFE-A9BE-DD2B98A85B3FQ38086339-E8DE1C69-360B-4CBB-B1B6-2F499316A2E2Q38121142-C68E5ED7-AFFD-493C-949F-4E09B961522CQ38170557-C98D51D4-34DA-4314-91F7-8FB4FCB4855DQ38187914-106A5F97-1F81-4356-8A82-C92446B91AF9Q38367560-1937F447-46AC-4CE9-BEDB-23110E75A7C5Q38394008-DF30C492-B010-4CB0-8859-75266BE2A3FAQ38829519-9C08BDD5-4D63-4131-8C02-2DE478B2ED56Q40401599-93DBE873-2B4B-49D6-A0E9-E78A842BE60AQ40679646-0F89DE77-261F-4B68-8314-EAE3C9190E13Q42095262-47F3660A-2BDD-4846-AA88-6A2DA2AED100Q43636170-01F204EC-DB87-4483-9446-73EB77C8858DQ43770717-1C29DCD2-A3F5-43C4-A2EA-A25B0C2333EDQ44321619-18359622-535A-4F7D-B12B-7ACA768FBDCBQ47644739-894E241E-5ED5-413F-A04B-C28B19681639Q50002566-7ACC0176-2B4A-4FD5-BFB8-2DACBE2D1BF8Q50797885-58131E48-B32B-44CF-AD26-F382B7CB586FQ51063911-E116A598-0F2E-47C6-B566-9068D76CDA69Q52628309-FF245A02-2CC6-4887-A557-24084A3A1210
P2860
Antimicrobial treatment of nosocomial meticillin-resistant Staphylococcus aureus (MRSA) pneumonia: current and future options.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 17 August 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Antimicrobial treatment of nos ...... a: current and future options.
@en
Antimicrobial treatment of nosocomial meticillin-resistant Staphylococcus aureus
@nl
type
label
Antimicrobial treatment of nos ...... a: current and future options.
@en
Antimicrobial treatment of nosocomial meticillin-resistant Staphylococcus aureus
@nl
prefLabel
Antimicrobial treatment of nos ...... a: current and future options.
@en
Antimicrobial treatment of nosocomial meticillin-resistant Staphylococcus aureus
@nl
P1476
Antimicrobial treatment of nos ...... a: current and future options.
@en
P304
P356
10.1016/J.IJANTIMICAG.2010.06.045
P577
2010-08-17T00:00:00Z